JW Pharmaceutical Corp
KRX:001060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
JW Pharmaceutical Corp
Cost of Revenue
JW Pharmaceutical Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JW Pharmaceutical Corp
KRX:001060
|
Cost of Revenue
-₩416B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
Yuhan Corp
KRX:000100
|
Cost of Revenue
-₩1.5T
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cost of Revenue
-₩42.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-85%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cost of Revenue
-₩663.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cost of Revenue
-₩122.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cost of Revenue
-₩20.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
JW Pharmaceutical Corp
Glance View
JW PHARMACEUTICAL Corp. engages in the development, manufacture, and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The firm also researches and develops anticancer drugs.
See Also
What is JW Pharmaceutical Corp's Cost of Revenue?
Cost of Revenue
-416B
KRW
Based on the financial report for Dec 31, 2025, JW Pharmaceutical Corp's Cost of Revenue amounts to -416B KRW.
What is JW Pharmaceutical Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-4%
Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for JW Pharmaceutical Corp have been -2% over the past three years , -2% over the past five years , and -4% over the past ten years .
